|
Chỉ định và Liều dùng
Oral
Malignant disease Adult: Initially, 300-400 mg/day. Maintenance: 50-150 mg/day.
|
|
Chống chỉ định
Pregnancy, lactation; acute infection, bone-marrow aplasia, drug or radiation-induced urothelial toxicity.
|
|
Thận trọng
Elderly and debilitated patients; renal and hepatic impairment; DM. Patients who have undergone adrenalectomy. Regular urinalysis and haematological profile may be required. Reduce urotoxicity by increasing hydration, maintaining urine output at 100 ml/hr and using mesna but care should be taken to avoid water retention and intoxication.
|
|
Tác dụng không mong muốn
Myelosuppression; thrombocytopenia, anaemia; nausea, vomiting, mucositis; alopecia; hyperpigmenation. Disturbances of carbohydrate metabolism; gonadal suppression; interstitial pulmonary fibrosis; cardiotoxicity (high doses).
Potentially Fatal: Haemorrhagic cystitis (after high dose or prolonged use). |
|
Tương tác
Doxorubicin and other cardiotoxic drugs may enhance cardiotoxicity. Increased risk of bone marrow suppression with allopurinol. Increased risk of renal impairment with amphotericin B, cisplatin. Possible increase in INR with warfarin.
|
|
Tác dụng
Description:
Mechanism of Action: Trofosfamide, a cyclophosphamide derivative, is an alkylating agent that inhibits cell division by cross-linking DNA strands and decreasing DNA synthesis. |
|
Phân loại MIMS
|
Đăng ký miễn phí để được tiếp tục đọc
Tiếp tục với Google
Đăng ký với email
Đã là thành viên?
Đăng nhập
Đăng xuất
